SCHEMBL84026

SCHEMBL84026

CCNc1nccc(C(C)C)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.40
PDPK1 O15530 1/20 0.39
HRH4 Q9H3N8 5/20 0.38
HTR3A P46098 1/20 0.37
IGF1R P08069 1/20 0.36
CDK4 P11802 1/20 0.36
CCND1 P24385 1/20 0.36
CCND2 P30279 1/20 0.36
CCND3 P30281 1/20 0.36
LMNA P02545 1/20 0.35
HTR7 P34969 1/20 0.35
MKNK1 Q9BUB5 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
CYP2C19 P33261 1/20 0.34
CASP7 P55210 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL84398 0.86 ACACB (0.42) ACACBHRH4HTR3AHTR7ALDH1A1
SCHEMBL84439 0.84 HRH4 (0.54) ACACBHRH4
SCHEMBL13384588 0.83 HRH4 (0.52) HRH4HTR7
SCHEMBL84443 0.81 HRH4 (0.44) HRH4MKNK1ALDH1A1
SCHEMBL12986127 0.81 CXCR4 (0.50) HRH4HTR3AHTR7ALDH1A1
SCHEMBL84065 0.81 MAPK9 (0.48) HRH4HTR7MKNK1ALDH1A1GAA
SCHEMBL14004971 0.81 HRH4 (0.50) HRH4
SCHEMBL84099 0.80 CDK4 (0.43) ACACBHRH4HTR3AIGF1RCDK4
SCHEMBL84017 0.79 ALDH1A1 (0.42) HRH4HTR3AALDH1A1CYP1A2CASP1
SCHEMBL84061 0.79 MAPK9 (0.43) PDPK1HRH4HTR3ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022100623-A1 NITROGEN-SUBSTITUTED HETEROCYCLIC THIOPHENE COMPOUNDS AND USE THEREOF 武汉人福创新药物研发中心有限公司 2022-05-19 WO disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 US disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-8865732-B2 Heterocyclic compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 US disclosed
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof NOVARTIS AG (CH) 2013-08-15 US disclosed
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 US disclosed
US-7696210-B2 Gonadotropin releasing hormone receptor antagonists WYETH (US) 2010-04-13 US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 ACACB 199/4885PDPK1 831/4885HRH4 3580/4885
US-20100003246-A1 Novel heterocyclic compounds and uses therof BRAF, ARAF, KRAS ACACB 1921/4885PDPK1 253/4885HRH4 2437/4885
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof BRAF, RAF1, HRAS ACACB 1032/4885PDPK1 94/4885HRH4 3096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.